Welcome to our dedicated page for Redhill Biopharm SEC filings (Ticker: RDHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RedHill Biopharma Ltd. (Nasdaq: RDHL) SEC filings page on Stock Titan provides centralized access to the company’s Form 20-F annual reports and Form 6-K current reports, which together document its regulatory, clinical, commercial and financing activities. As a foreign private issuer focused on gastrointestinal diseases, infectious diseases and oncology, RedHill uses Form 6-K extensively to furnish press releases and other information to the U.S. Securities and Exchange Commission.
In these filings, investors can review detailed disclosures about Talicia®, RedHill’s FDA-approved oral therapy for Helicobacter pylori infection in adults, including its indication, QIDP-based market exclusivity, patent coverage and ex-U.S. licensing arrangements. Filings also describe the company’s late-stage development programs: opaganib (ABC294640), a sphingosine kinase-2 selective inhibitor with anticancer, anti-inflammatory and antiviral activity; RHB-102 (Bekinda®), an extended-release ondansetron formulation for multiple gastrointestinal and oncology-support indications; RHB-204, an optimized formulation of RHB-104 for Crohn’s disease and pulmonary nontuberculous mycobacteria disease; and RHB-107 (upamostat), a host-directed serine protease inhibitor in late-stage development for non-hospitalized symptomatic COVID-19 and other conditions.
RedHill’s Form 6-K reports also cover capital markets and financing transactions, such as at-the-market offering programs, purchase agreements for American Depositary Shares, and amendments to ownership thresholds. Additional filings document Nasdaq listing compliance matters, including notifications related to the minimum stockholders’ equity requirement and subsequent confirmation of regained compliance, as well as legal proceedings like New York Supreme Court judgments and Korean court attachment orders in the Kukbo dispute.
Stock Titan’s interface is designed to surface these filings as they are furnished to EDGAR and to pair them with AI-powered summaries that explain the key points of lengthy documents. Users can quickly identify items such as quarterly and interim financial information, registration statement incorporations by reference, and governance or financing updates, while drilling down into full-text filings when more detail is needed.
RedHill Biopharma Ltd. reported that at its Extraordinary General Meeting of Shareholders held on March 5, 2026, all resolutions proposed to shareholders were duly approved. The company also states that this report is incorporated by reference into multiple existing Form S-8 and Form F-3 registration statements previously filed with the U.S. securities regulator.
RedHill Biopharma reports that full U.S. sales and operational launch of Talicia has begun under a joint commercialization agreement with Cumberland Pharmaceuticals. The launch is managed by Talicia Holdings Inc. (THI), a jointly controlled operating entity owned 70% by RedHill and 30% by Cumberland.
This operational start follows a previously announced joint commercialization model that included Cumberland’s $4 million strategic investment. The partners aim to accelerate Talicia’s market penetration and reach by integrating commercial resources and coordinating promotion activities.
Talicia is the only FDA‑approved all‑in‑one, low‑dose rifabutin‑based therapy for H. pylori infection and is listed as an empiric first‑line treatment option in the 2024 American College of Gastroenterology guideline. H. pylori affects about 35% of U.S. adults, with an estimated 1.6 million patients treated annually, making this a large target market. RedHill is also pursuing Talicia approvals and licensing opportunities in additional territories, including the UK, the Middle East, and other ex‑U.S. markets.
RedHill Biopharma is registering up to 6,465,559 ADSs for resale by YA II PN, LTD. under a standby equity purchase arrangement. The ADSs cover up to 5,000,000 Advance Shares, 386,593 Initial Equity Shares, 590,446 ADSs from pre-funded warrants and 488,520 Commitment Shares.
Under the Purchase Agreement, YA has committed, subject to conditions and ownership caps, to buy up to $25.0 million of ADSs over 36 months, plus $1.0 million already raised via Initial Equity Shares and pre-funded warrants. As of January 21, 2026, 5,112,885 ADSs were outstanding; if all 6,465,559 registered ADSs were issued, they would represent about 55.84% of outstanding ADSs.
RedHill Biopharma Ltd. has called an Extraordinary General Meeting for March 5, 2026 in Tel Aviv to vote on four key proposals. Shareholders will be asked to approve RSU grants to four independent non-executive directors, including 9,000 ADSs each for Drs. Reed, Cabilly and Mamluk and 12,500 ADSs for Ofer Tsimchi, vesting quarterly over two years. A separate proposal seeks approval for 38,000 ADS RSUs for CEO and Chairman Dror Ben-Asher and 27,000 ADS RSUs for Chief Commercial Officer and director Rick D. Scruggs, also vesting over two years. Another proposal would increase authorized share capital from NIS 1.6 billion to NIS 5.0 billion, raising the ordinary share authorization from 159,994,000,000 to 499,994,000,000 shares. Holders of record of ADSs as of January 23, 2026, when 51,128,851,000 ordinary shares (5,112,885 ADSs) were outstanding, may vote, with a special majority requirement applying to the CEO grant.
RedHill Biopharma Ltd. has filed a resale registration for up to 6,465,559 American Depositary Shares (ADSs) that may be offered from time to time by YA II PN, Ltd. under a standby equity purchase arrangement. The total covers 5,000,000 ADSs that RedHill may sell to YA, plus ADSs already issued or issuable as Initial Equity Shares, Pre-Funded Warrants and Commitment Shares.
RedHill will not receive proceeds from YA’s resale of these ADSs, but may raise up to
The filing highlights dilution and price pressure risks from this structure, alongside other financing tools such as an existing
RedHill Biopharma Ltd. has called an extraordinary general meeting of shareholders for March 5, 2026, to be held at its Tel-Aviv offices. The notice states that only holders of record of ADSs at the close of business on January 23, 2026 are entitled to receive notice and vote.
The board of directors recommends that shareholders vote “FOR” the proposals described in the proxy materials. ADS holders are asked to return their proxies by the deadline on their proxy form, and shareholders may submit written position statements to the company by February 23, 2026.
If a quorum is not reached within half an hour of the scheduled time, the meeting will be adjourned to a later date as determined by the board. The notice and related documents will be available on RedHill’s website and on the SEC website.
RedHill Biopharma reports new preclinical in vivo data suggesting its investigational drug opaganib may help overcome resistance to venetoclax, a key therapy for Chronic Lymphocytic Leukemia (CLL). In a mouse model, adding opaganib, a potent sphingosine kinase 2 (SPHK2) inhibitor, to venetoclax reduced CLL cells (CD19⁺, CD5⁺) by 50% versus controls and lowered certain T cell populations and PD1 expression, indicating a potential role in mitigating resistance to BCL‑2 inhibition.
The company highlights opaganib as a first‑in‑class, orally administered, host‑directed agent with anticancer, antiviral and anti‑inflammatory activity, with a safety and tolerability profile demonstrated in more than 470 clinical and expanded access participants. Opaganib is being evaluated in a Phase 2 trial with darolutamide in advanced prostate cancer, holds FDA orphan designations in cholangiocarcinoma and neuroblastoma, and is backed by several U.S. government programs, including BARDA, across oncology, radiation injury and pandemic preparedness indications.
RedHill Biopharma Ltd. (RDHL) reports that on November 26, 2025 it filed a prospectus supplement to increase the maximum aggregate offering amount of American Depositary Shares (ADSs) that may be issued and sold under its existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC, originally entered into on February 3, 2025. Each ADS represents 10,000 ordinary shares of RedHill, with a par value of NIS 0.01 per share.
The report also notes that legal opinions and related consents from Goldfarb Gross Seligman & Co. and Haynes and Boone, LLP are filed as exhibits, and that this Form 6-K is incorporated by reference into multiple existing RedHill registration statements on Forms S-8 and F-3.
RedHill Biopharma Ltd. is increasing the maximum aggregate amount of American Depositary Shares it may sell under its at-the-market offering agreement with H.C. Wainwright & Co. to $352,267. Each ADS represents ten thousand Ordinary Shares, and this new limit applies only to future sales under the existing Sales Agreement.
As of this supplement, the company’s public float under Form F-3 was valued at $11,448,803.52, based on 45,431,765,990 Ordinary Shares held by non-affiliates, which would be represented by 4,543,176 ADSs at a price of $2.52 per ADS as of October 1, 2025. Over the prior 12 months, RedHill sold 890,001 ADSs via the program for approximately $3.4 million in gross proceeds, and any further increases in sale capacity will require an additional prospectus supplement.